Beautiful Virgin Islands

Tuesday, Jul 22, 2025

Rare condition listed as possible side effect of Covid-19 shots

Rare condition listed as possible side effect of Covid-19 shots

The EU’s drug watchdog is warning of a ‘very rare’ spinal cord inflammation possibly related to the AstraZeneca and J&J vaccines
The European Medicines Agency wants to put warning labels on Covid-19 jabs made by AstraZeneca and Johnson & Johnson, saying there was a “reasonable possibility” they may have caused a spinal inflammation on rare occasions.

Following three days of meetings and discussions, the EMA’s Pharmacovigilance Risk Assessment Committee (PRAC) said on Friday it wants to include a warning for “very rare cases of transverse myelitis (TM) reported following vaccination” with the Vaxzevria and Janssen jabs. It is also adding the condition as an “adverse reaction of unknown frequency” to the vaccine profile.

The EMA describes TM as a rare neurological condition characterized by an “inflammation of one or both sides of the spinal cord,” which can cause weakness in arms or legs, tingling, numbness, pain – or loss of pain sensation – and problems with bowel and bladder function.

The recommendation comes after the PRAC reviewed available information on reported cases worldwide and scientific literature, concluding that “a causal relationship between these two vaccines and transverse myelitis is at least a reasonable possibility.” However, it said the “benefit-risk profile of both vaccines remains unchanged.”

The warning is intended to “raise awareness among healthcare professionals and people receiving the vaccines.” Doctors were told to be on alert for signs and symptoms of TM, while recipients were urged to “seek immediate medical attention” if they develop the symptoms.

Last month, the EMA approved the Janssen jab as a booster for people aged 18 and older, to be given at least two months after previous vaccinations.

The PRAC also revised the product information for AstraZeneca’s Vaxzevria, to reflect that far fewer cases of thrombosis with thrombocytopenia (TTS) – blood clotting with a low platelet count – have been recorded after the second dose of the jab, compared to the first.

The use of AstraZeneca’s vaccine, developed with Oxford University, has already been scaled back due to the “ultra rare” side effect, which UK government statistics last summer estimated at around 14.9 per million doses of the jab. A study published in December blamed a very specific issue with Vaxzevria’s adenovirus vector.
Newsletter

Related Articles

Beautiful Virgin Islands
0:00
0:00
Close
Japanese Prime Minister Vows to Stay After Coalition Loses Upper House Majority
Pogacar Extends Dominance with Stage Fifteen Triumph at Tour de France
CEO Resigns Amid Controversy Over Relationship with HR Executive
Man Dies After Being Pulled Into MRI Machine Due to Metal Chain in New York Clinic
NVIDIA Achieves $4 Trillion Valuation Amid AI Demand
US Revokes Visas of Brazilian Corrupted Judges Amid Fake Bolsonaro Investigation
U.S. Congress Approves Rescissions Act Cutting Federal Funding for NPR and PBS
North Korea Restricts Foreign Tourist Access to New Seaside Resort
Brazil's Supreme Court Imposes Radical Restrictions on Former President Bolsonaro
Centrist Criticism of von der Leyen Resurfaces as she Survives EU Confidence Vote
Judge Criticizes DOJ Over Secrecy in Dropping Charges Against Gang Leader
Apple Closes $16.5 Billion Tax Dispute With Ireland
Von der Leyen Faces Setback Over €2 Trillion EU Budget Proposal
UK and Germany Collaborate on Global Military Equipment Sales
Trump Plans Over 10% Tariffs on African and Caribbean Nations
Flying Taxi CEO Reclaims Billionaire Status After Stock Surge
Epstein Files Deepen Republican Party Divide
Zuckerberg Faces $8 Billion Privacy Lawsuit From Meta Shareholders
FIFA Pressured to Rethink World Cup Calendar Due to Climate Change
SpaceX Nears $400 Billion Valuation With New Share Sale
Microsoft, US Lab to Use AI for Faster Nuclear Plant Licensing
Trump Walks Back Talk of Firing Fed Chair Jerome Powell
Zelensky Reshuffles Cabinet to Win Support at Home and in Washington
"Can You Hit Moscow?" Trump Asked Zelensky To Make Putin "Feel The Pain"
Irish Tech Worker Detained 100 days by US Authorities for Overstaying Visa
Dimon Warns on Fed Independence as Trump Administration Eyes Powell’s Succession
Church of England Removes 1991 Sexuality Guidelines from Clergy Selection
Superman Franchise Achieves Success with Latest Release
Hungary's Viktor Orban Rejects Agreements on Illegal Migration
Jeff Bezos Considers Purchasing Condé Nast as a Wedding Gift
Ghislaine Maxwell Says She’s Ready to Testify Before Congress on Epstein’s Criminal Empire
Bal des Pompiers: A Celebration of Community and Firefighter Culture in France
FBI Chief Kash Patel Denies Resignation Speculations Amid Epstein List Controversy
Air India Pilot’s Mental Health Records Under Scrutiny
Google Secures Windsurf AI Coding Team in $2.4 Billion Licence Deal
Jamie Dimon Warns Europe Is Losing Global Competitiveness and Flags Market Complacency
South African Police Minister Suspended Amid Organised Crime Allegations
Nvidia CEO Claims Chinese Military Reluctance to Use US AI Technology
Hong Kong Advances Digital Asset Strategy to Address Economic Challenges
Australia Rules Out Pre‑commitment of Troops, Reinforces Defence Posture Amid US‑China Tensions
Martha Wells Says Humanity Still Far from True Artificial Intelligence
Nvidia Becomes World’s First Four‑Trillion‑Dollar Company Amid AI Boom
U.S. Resumes Deportations to Third Countries After Supreme Court Ruling
Excavation Begins at Site of Mass Grave for Children at Former Irish Institution
Iranian President Reportedly Injured During Israeli Strike on Secret Facility
EU Delays Retaliatory Tariffs Amid New U.S. Threats on Imports
Trump Defends Attorney General Pam Bondi Amid Epstein Memo Backlash
Renault Shares Drop as CEO Luca de Meo Announces Departure Amid Reports of Move to Kering
Senior Aides for King Charles and Prince Harry Hold Secret Peace Summit
Anti‑Semitism ‘Normalised’ in Middle‑Class Britain, Says Commission Co‑Chair
×